started · updated
Vaxcyte shares surge after successful Phase 3 vaccine trial results
Vaxcyte, Inc. shares rose over 30% following the announcement of successful Phase 3 clinical trial results for its adult pneumococcal vaccine candidate, VAX-31. The OPUS-1 trial met primary immunogenicity endpoints in participants aged 50 and older, demonstrating non-inferiority across 28 serotypes shared with PCV20 and PCV21, and superiority in three unique serotypes.
The company reported a safety profile similar to existing vaccines. While these results do not constitute FDA approval, Vaxcyte plans to release results from its OPUS-2 and OPUS-3 trials in the first half of 2027, with the goal of submitting a Biologics License Application in the first half of 2028.
Following the news, several financial institutions adjusted their outlooks. Needham & Company LLC raised its price target for Vaxcyte from $110 to $122, while Guggenheim increased its target from $116 to $125. The company also announced a public offering of common stock, prepaid warrants, and convertible senior notes totaling approximately $1 billion.
Entities
Bank of America · FDA · Guggenheim · Needham & Company LLC · Vaxcyte, Inc.